Phase 2 Trial of Bevacizumab in Combination With Pemetrexed
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This trial evaluated the safety of combining bevacizumab and pemetrexed in non-small cell
lung cancer (NSCLC) patients with stable brain metastases as second-line chemotherapy, while
evaluating progression-free survival (PFS) and overall survival (OS).
Phase:
Phase 2
Details
Lead Sponsor:
Heather Wakelee
Collaborators:
Eli Lilly and Company Genentech, Inc.
Treatments:
Bevacizumab Dexamethasone Folic Acid Hydroxocobalamin Pemetrexed Vitamin B 12 Vitamin B Complex Vitamins